One unit of 96372 is reported per injection encounter
Results can be seen in as little as 24-48 hours, depending on the severity of the injury
follow sterile compounding guidelines Injection site: Abdomen subcutaneous, rotating sites each injection Stacking: Often evaluated in combination with CJC-1295/Ipamorelin for complementary anabolic-lipolytic effects, or with BPC-157 for tissue repair support These parameters reflect research protocols and published clinical trial data
The two peptides operate through largely complementary rather than overlapping mechanisms, which suggests a potentially additive or even synergistic effect in tissue repair models
Safety across the full program was consistently favorable: adverse events, primarily mild headache and gastrointestinal symptoms, occurred at rates comparable to placebo, with no treatment-related discontinuations, no IGF-1 elevation, and no impact on glucose metabolism